Cell>Point is a late stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases.
The company was established in 2001 to develop and commercialize molecular imaging and targeted therapeutics based on 5 platform technologies licensed from The University of Texas MD Cancer Center.
Cell>Point’s lead product in clinical development is ethylenedicysteine-glucosamine which the company registered under the trademark “Oncardia”. With applications in cancer and cardiovascular disease, Oncardia can be radiolabeled or complexed with cold metals to create a range of nuclear imaging and therapeutic products. Oncardia’s mechanism of action allows it to target the diseased cell and then deliver its radionuclide or cold metal into the cell nucleus. Cell>Point refers to this as intra-nuclear therapy. Oncardia can be conveniently labeled with technetium-99m (99mTc) for imaging with SPECT and SPECT/CT camera systems or gallium-68 (68Ga) for imaging with PET and PET/CT camera systems. For therapy, there are two choices. Oncardia can be complexed with a cold metal for intra-nuclear metallic therapy such as platinum or rhenium-187 (187Re), or it can be labeled with radionuclides like lutetium-177 or rhenium-188 for intra-nuclear radiotherapy.
Platform Technologies Acquired from the University of Texas M.D. Anderson Cancer Center
Platform Technologies Are Based on Chelation Chemistry
Molecular Imaging Agents
Targeted Intra-Nuclear Therapeutics
Patents Granted Worldwide
Patents Pending
Theranostic medicine is a major step forward in making personalized medicine a reality. At Cell>Point, theranostics is the combination of target specific diagnostic imaging and compatible target specific therapy at the molecular level.
ExploreUntil Oncardia, the only way to image cancer is with expensive PET cameras. This is about to change.
ExploreNuclear cardiology imaging needs an agent that eliminates the stress test. At Cell>Point we are making that a reality.
ExploreCENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program…
ReadCENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted…
ReadCENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its…
ReadCENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with…
Read